var data={"title":"Pharmacology of antimicrobial agents for treatment of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pharmacology of antimicrobial agents for treatment of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/contributors\" class=\"contributor contributor_credentials\">Richard H Drew, PharmD, MS, FCCP, FIDP</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/contributors\" class=\"contributor contributor_credentials\">David C Hooper, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 30, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pharmacologic properties of alternatives to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> for use in treatment of invasive infections due to methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) and vancomycin-resistant enterococcus (VRE) will be reviewed here. The topic discusses use of the following drugs for monotherapy: <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>, <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>, <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a>, <a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">dalbavancin</a>, <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a>, <a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">tedizolid</a>, <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>, and <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a>.</p><p>Issues related to the role of these agents for treatment of specific infections are discussed in detail separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;</a> and <a href=\"topic.htm?path=treatment-of-enterococcal-infections\" class=\"medical medical_review\">&quot;Treatment of enterococcal infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H746396028\"><span class=\"h1\">VANCOMYCIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> are discussed separately. (See <a href=\"topic.htm?path=vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults\" class=\"medical medical_review\">&quot;Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13034132\"><span class=\"h1\">DAPTOMYCIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> is a cyclic lipopeptide that is active against gram-positive organisms including streptococci, enterococci (including vancomycin-resistant enterococci [VRE]), methicillin-sensitive <em>S. aureus </em>(MSSA), and methicillin-resistant <em>S. aureus </em>(MRSA) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/1,2\" class=\"abstract_t\">1,2</a>]. While <em>S. aureus</em> isolates with complete or intermediate resistance to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> in vitro have maintained susceptibility to daptomycin, MRSA isolates with increased minimum inhibitory concentrations (MICs) or prior exposure to vancomycin may also exhibit reduced susceptibility to daptomycin [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/3,4\" class=\"abstract_t\">3,4</a>]. However, elevations in vancomycin MICs have not been useful in predicting outcomes in daptomycin-treated patients [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/5,6\" class=\"abstract_t\">5,6</a>].</p><p><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> is US Food and Drug Administration (FDA) approved for the treatment of adults with complicated skin and skin structure infections due to gram-positive pathogens, for bacteremia with or without right-sided endocarditis in adults due to <em>S. aureus</em>, and for <em>S. aureus</em> bacteremia in pediatric patients [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Clinical experience with use of daptomycin for other forms of infections due to MRSA and VRE and experience in pediatric patients has been described [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p class=\"headingAnchor\" id=\"H13034159\"><span class=\"h2\">Mechanism and pharmacodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> is rapidly bactericidal. Its primary mechanism of action is calcium-dependent depolarization of bacterial cell wall [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Daptomycin has a lipophilic tail, which binds and inserts itself into the bacterial membrane and forms a channel that causes efflux of intracellular potassium with subsequent depolarization of the cell membrane. The antimicrobial activity of daptomycin is concentration dependent and is associated with a prolonged postantibiotic effect [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/12-14\" class=\"abstract_t\">12-14</a>]. Daptomycin is inactivated by alveolar surfactants and therefore should not be used for pulmonary infections [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/15\" class=\"abstract_t\">15</a>].</p><p>The mechanisms of resistance to <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> are not fully understood [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/16\" class=\"abstract_t\">16</a>]. Daptomycin resistance appears to emerge gradually via multiple steps, resulting in a heteroresistant subpopulation with elevated MIC to daptomycin [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/3\" class=\"abstract_t\">3</a>]. Altered cell membrane potential due to changes in cell membrane surface charge has been shown to lead to reduced daptomycin binding to the cell membrane and reduced susceptibility to daptomycin-induced depolarization [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/17\" class=\"abstract_t\">17</a>].</p><p>Treatment-emergent <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> resistance has been associated with prolonged therapy in MRSA bacteremia and subtherapeutic daptomycin concentrations in bone tissues with retained infected bone [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/18-20\" class=\"abstract_t\">18-20</a>]. Sporadic, treatment-emergent resistance in vancomycin-resistant <em>Enterococcus faecium</em> has also been reported [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H13034166\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> has poor oral bioavailability and must be administered parenterally [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/8\" class=\"abstract_t\">8</a>]. Daptomycin rapidly binds to serum albumin (90 to 95 percent) and distributes primarily in the vascular space [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/22\" class=\"abstract_t\">22</a>]. The high affinity for serum proteins and a small volume of distribution (0.1 <span class=\"nowrap\">L/kg)</span> prevents the drug from effectively crossing host cell membranes or select tissues [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/22\" class=\"abstract_t\">22</a>]. For example, the penetration of daptomycin into lung tissue and infected bone are low (relative to its serum concentration, 9 and 6 percent, respectively) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/18,23\" class=\"abstract_t\">18,23</a>]. Daptomycin poorly penetrates into the cerebrospinal fluid, even with meningeal inflammation [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/24\" class=\"abstract_t\">24</a>]. Thus, reduced tissue penetration may limit the routine use of daptomycin for infections such as osteomyelitis and meningitis, despite case reports of clinical cures [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/25,26\" class=\"abstract_t\">25,26</a>].</p><p><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> has a half-life of approximately 8 hours in adults and approximately 5 to 7 hours in children 1 to 11 years old; the drug is primarily excreted unchanged via the kidneys (80 percent) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/8,14,27,28\" class=\"abstract_t\">8,14,27,28</a>].</p><p class=\"headingAnchor\" id=\"H13034173\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common adverse events reported in a phase III clinical study included constipation, nausea, and injection site reactions (6 percent) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/27\" class=\"abstract_t\">27</a>]. <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> administration has been associated with elevations in creatine phosphokinase (CPK) and myopathy. In phase III studies, the prevalence of asymptomatic CPK elevation and symptomatic myopathy were 2.8 and 0.2 percent, respectively [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/28\" class=\"abstract_t\">28</a>]. Daptomycin has also been associated with rhabdomyolysis in case reports [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/29\" class=\"abstract_t\">29</a>]. Vomiting was a common adverse event in the pediatric trials of daptomycin.</p><p>Daptomycin-related muscle complications often manifest with muscle pains within one week of starting therapy [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/30-33\" class=\"abstract_t\">30-33</a>]. <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> should be discontinued if muscle-related complications are suspected or identified. Symptoms generally resolve within two to three days after discontinuation of the drug, although CPK elevations may persist up to two weeks.</p><p>Eosinophilic pneumonia has been described with the use of <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, generally manifesting as dyspnea, hypoxia, and fever two to four weeks after treatment initiation. Pulmonary infiltrates or organizing pneumonia and chronic pneumonitis have also been described [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/34\" class=\"abstract_t\">34</a>]. Eosinophilic pneumonia is reversible with drug discontinuation. Prolonged administration has rarely been associated with neutropenia that was reversible upon drug discontinuation [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/35\" class=\"abstract_t\">35</a>].</p><p class=\"headingAnchor\" id=\"H13034180\"><span class=\"h2\">Use in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Animal studies using high-dose <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> therapy have not revealed any teratogenicity. There are no adequate or well-controlled studies in pregnant women.</p><p class=\"headingAnchor\" id=\"H13034187\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> is neither an inducer nor an inhibitor of the hepatic CYP450 system. Concomitant administration of HMG-CoA reductase inhibitors (&quot;statins&quot;) may increase the risk of CPK elevation and myopathy.</p><p><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> may falsely prolong prothrombin time (PT) and elevate international normalized ratio (INR), dependent on daptomycin concentrations and the recombinant thromboplastin reagents used [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/36\" class=\"abstract_t\">36</a>].</p><p class=\"headingAnchor\" id=\"H13034194\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For treatment of complicated skin and skin-structure infections in adult patients, 4 <span class=\"nowrap\">mg/kg</span> intravenously (IV) once daily should be administered. A higher dose (ie, 6 <span class=\"nowrap\">mg/kg</span> IV once daily) is used in the treatment of bloodstream infections and right-sided endocarditis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Because of its concentration-dependent activity, use of higher doses (&ge;8 <span class=\"nowrap\">mg/kg/day,</span> up to as much as 12 <span class=\"nowrap\">mg/kg/day)</span> have been reported but are not FDA approved. Use of such high doses should be restricted to cases of life-threatening invasive staphylococcal infections (such as infective endocarditis) refractory or intolerant to alternate therapy.</p><p>The optimal dose to treat invasive enterococcal infections is unknown, especially in isolates with MICs at or near the MIC breakpoint of 4 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/37,38\" class=\"abstract_t\">37,38</a>]. Higher daily doses (&gt;9 <span class=\"nowrap\">mg/kg)</span> have been associated with reduced mortality in VRE bacteremia [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/39,40\" class=\"abstract_t\">39,40</a>].</p><p>In children, once-daily doses used for complicated skin and skin-structure infections range from 5 <span class=\"nowrap\">mg/kg</span> for adolescents 12 to 17 years old, 7 <span class=\"nowrap\">mg/kg</span> for children 7 to 11 years old, 9 <span class=\"nowrap\">mg/kg</span> for children 2 to 6 years old, and 10 <span class=\"nowrap\">mg/kg</span> for toddlers 1 to &lt;2 years old. For <em>S. aureus</em> bacteremia, once-daily doses are 7 <span class=\"nowrap\">mg/kg</span> for adolescents 12 to 17 years old, 9 <span class=\"nowrap\">mg/kg</span> for children 7 to 11 years old, and 12 <span class=\"nowrap\">mg/kg</span> for children 1 to 6 years old.</p><p>The dosing interval should be increased to every 48 hours in adult patients with severe renal impairment (creatinine clearance of &lt;30 <span class=\"nowrap\">mL/minute)</span>. In patients receiving intermittent hemodialysis, the dose should be given after hemodialysis whenever possible. No adjustment is required for mild to moderate hepatic dysfunction. Guidelines for the adjustment of dose in children with renal impairment are not available.</p><p class=\"headingAnchor\" id=\"H13034201\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients receiving <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> therapy should undergo baseline measurement of renal function and CPK followed by weekly monitoring. Patients should also be evaluated regularly for clinical evidence of myopathy. The drug should be discontinued in patients with symptomatic myopathy and CPK &ge;5 times the upper limit of normal (ULN) or in asymptomatic patients with CPK &ge;10 times the ULN.</p><p><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> minimum concentration (Cmin) &ge;24 <span class=\"nowrap\">mg/L</span> has been associated with an increased probability of a CPK elevation [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/41\" class=\"abstract_t\">41</a>]; however, serum concentration determinations are not routinely available in most settings.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">LINEZOLID</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> is a synthetic oxazolidinone with in vitro activity against a variety of gram-positive organisms including streptococci, enterococci (including vancomycin-resistant enterococci [VRE]), coagulase-negative staphylococci, methicillin-sensitive <em>S. aureus </em>(MSSA), and methicillin-resistant <em>S. aureus</em> (MRSA) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/42-46\" class=\"abstract_t\">42-46</a>].</p><p>The US Food and Drug Administration (FDA) has approved <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> for the treatment of adults and children with pneumonia (nosocomial and community acquired) and skin and skin structure infections (both complicated and uncomplicated), including those due to MRSA and vancomycin-resistant <em>E. faecium</em> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/47,48\" class=\"abstract_t\">47,48</a>]. Linezolid is not approved for the treatment of catheter-related bloodstream infections [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/49\" class=\"abstract_t\">49</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Mechanism, resistance, and pharmacodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> is bacteriostatic against most organisms. It binds to the 50S subunit of the bacterial ribosome, inhibiting bacterial protein synthesis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/44,50\" class=\"abstract_t\">44,50</a>]. In addition, linezolid suppresses the production of bacterial toxins such as Panton-Valentine leukocidin, alpha-hemolysin, and toxic shock syndrome toxin-1 [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/51-53\" class=\"abstract_t\">51-53</a>]. The antimicrobial activity of linezolid is best predicted by the ratio of the 24-hour area under the time-concentration curve to minimum inhibitory concentration (MIC) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/54,55\" class=\"abstract_t\">54,55</a>]. It displays moderate postantibiotic effects against <em>S. aureus</em> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/56\" class=\"abstract_t\">56</a>].</p><p><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> may fail to bind its bacterial target site in the presence of single-point mutations in the bacterial 23S rRNA of the 50S subunit. While enterococci and <em>S. aureus </em>with in vitro resistance to linezolid have been reported, in vitro resistance in <em>S. aureus</em> is infrequent [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/57-59\" class=\"abstract_t\">57-59</a>]. Coagulase-negative staphylococci isolates, mainly <em>S. epidermidis</em>, account for the majority of gram-positive organisms with elevated MIC to linezolid [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/60\" class=\"abstract_t\">60</a>]. Mutations in 23S rRNA that confer resistance to linezolid can produce cross-resistance to <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a> and <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a>, which also bind to the same 23S rRNA domain [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/57\" class=\"abstract_t\">57</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The systemic absorption of <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> approaches 100 percent following oral administration [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/61\" class=\"abstract_t\">61</a>]. Linezolid binds poorly to serum proteins (31 percent), and thus it penetrates well into most body compartments (including bone, alveoli, and the cerebrospinal space) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/61\" class=\"abstract_t\">61</a>]. As a result, linezolid has a volume of distribution that is similar to total body water (30 to 50 L). The overall tissue distribution of linezolid is stable and is not adversely affected by sepsis or peripheral vascular disease [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/55,62-65\" class=\"abstract_t\">55,62-65</a>].</p><p><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> does not interact with the cytochrome P450 oxidative system but rather undergoes hepatic oxidative metabolism into two inactive metabolites. Its metabolites are eliminated predominantly in the urine [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/55\" class=\"abstract_t\">55</a>]. The elimination half-life of linezolid is five to seven hours in adults and less than five hours in children [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/61,66\" class=\"abstract_t\">61,66</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common adverse effects of <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> in phase III clinical trials were mild symptoms of diarrhea (4.3 percent), nausea (3.4 percent), headache (2.2 percent), and altered taste (1.2 percent) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/67\" class=\"abstract_t\">67</a>]. Other important adverse effects related to linezolid use include myelosuppression, neuropathy (peripheral and optic), lactic acidosis, and the potential for serotonin syndrome (when administered concomitantly with serotonergic antidepressants). (See <a href=\"#H7\" class=\"local\">'Drug interactions'</a> below.)</p><p>Linezolid-induced thrombocytopenia is the most frequently observed blood dyscrasia with <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> (occurring in up to one-third of adult recipients), although all blood cell lineages may be depressed with prolonged and high cumulative doses of the drug [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/68-70\" class=\"abstract_t\">68-70</a>]. Risk factors for linezolid-induced myelosuppression include renal impairment, low baseline blood cell counts, and duration of therapy &gt;14 days [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/70-74\" class=\"abstract_t\">70-74</a>]. Administration of pyridoxine (B6) successfully reversed linezolid-induced thrombocytopenia in one report [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/75\" class=\"abstract_t\">75</a>] but did not prevent myelosuppression for treatment exceeding two weeks [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/76\" class=\"abstract_t\">76</a>]. Hematologic effects of linezolid may occur less commonly in children than in adults [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/77\" class=\"abstract_t\">77</a>].</p><p><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> has been associated with optic and peripheral neuropathy in some studies, generally following several weeks of use [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/78-81\" class=\"abstract_t\">78-81</a>]. Decreased visual acuity, development of scotomas, and diminished color perception have been reported [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/79\" class=\"abstract_t\">79</a>]. The pathogenesis of optic neuropathy is uncertain, although the clinical manifestations mirror the findings observed in the setting of ocular neuropathy due to nutritional deficiency and mitochondrial dysfunction [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/82\" class=\"abstract_t\">82</a>].</p><p>Mitochondrial impairment may account for two other uncommon adverse effects: peripheral neuropathy and lactic acidosis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/83-85\" class=\"abstract_t\">83-85</a>]. Linezolid-induced peripheral neuropathy usually manifests as a &quot;glove and stocking&quot; sensory impairment with a sensory-motor axonal pattern on nerve conduction studies [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/78,86\" class=\"abstract_t\">78,86</a>]. This adverse effect is time and dose dependent with the use of <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> and may not resolve after discontinuation of the drug [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/87\" class=\"abstract_t\">87</a>].</p><p>Several cases of linezolid-related lactic acidosis have been reported. In many patients, lactic acidosis occurred after 40 to 50 days on <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> therapy and was associated with nausea, vomiting, or generalized weakness [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/88\" class=\"abstract_t\">88</a>]. Discontinuation of linezolid usually resulted in resolution of lactic acidemia. It has been postulated that linezolid cross-interacts with human mitochondrial 16S RNA because of its resemblance to bacterial 23S rRNA [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/89\" class=\"abstract_t\">89</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Use in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some animal studies showed decreased fetal body weights and increased incidence of fusion of costal cartilages. There are no adequate and well-controlled studies in pregnant women [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/90\" class=\"abstract_t\">90</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> is a weak inhibitor of monoamine oxidase (MAO). Linezolid<em> </em>can precipitate serotonin toxicity when coadministered with nonselective MAO inhibitors, selective serotonin-reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or <a href=\"topic.htm?path=bupropion-drug-information\" class=\"drug drug_general\">bupropion</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/47,91-95\" class=\"abstract_t\">47,91-95</a>]. There are observational reports of safe coadministration [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/96\" class=\"abstract_t\">96</a>]. Most reports of linezolid-induced serotonin syndrome occurred within one week of starting linezolid therapy in conjunction with the administration of an SSRI [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/97\" class=\"abstract_t\">97</a>]. Deaths from this interaction have been reported [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/47\" class=\"abstract_t\">47</a>].</p><p>Linezolid-related serotonin toxicity can usually be managed by discontinuing <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>, the <span class=\"nowrap\">SSRIs/SNRIs,</span> or both. Some authors have reported successful treatment of serotonin toxicity with <a href=\"topic.htm?path=cyproheptadine-drug-information\" class=\"drug drug_general\">cyproheptadine</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/98\" class=\"abstract_t\">98</a>]. The median time to resolution of symptoms is usually 48 hours from the time of adjusting medications.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The adult dose of <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> is 600 mg intravenously or orally twice daily [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/99\" class=\"abstract_t\">99</a>]. The pediatric dose is 10 <span class=\"nowrap\">mg/kg</span> intravenously or orally either every 8 hours (&le;12 years of age) or every 12 hours (&gt;12 years of age). Linezolid does not require dosing adjustment in hepatic or renal impairment [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/100\" class=\"abstract_t\">100</a>]. However, high-flux exchange membranes can remove up to one-third of the serum level of linezolid during hemodialysis. For patients on hemodialysis, one of the two daily doses should be given after dialysis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/100\" class=\"abstract_t\">100</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Weekly complete blood counts should be monitored for patients receiving <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> therapy for more than 7 to 10 days [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/69\" class=\"abstract_t\">69</a>]. Some favor evaluating serum lactate in the setting of nausea <span class=\"nowrap\">and/or</span> reduced serum bicarbonate [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/68\" class=\"abstract_t\">68</a>]. Patients receiving prolonged courses of linezolid (ie, &gt;2 weeks) should be educated as to the early clinical symptoms of optic and peripheral neuropathy. (See <a href=\"#H5\" class=\"local\">'Adverse effects'</a> above.)</p><p>Variability in <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> serum concentrations among critically ill patients has been observed [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/101\" class=\"abstract_t\">101</a>]; however, such testing is not routinely available and interpretive criteria have not been established.</p><p>Administration of <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> with MAO inhibitors or <span class=\"nowrap\">SSRIs/SNRIs</span> should be avoided. If they are coadministered, close monitoring for signs and symptoms of serotonin syndrome is critical. (See <a href=\"topic.htm?path=serotonin-syndrome-serotonin-toxicity\" class=\"medical medical_review\">&quot;Serotonin syndrome (serotonin toxicity)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1402177436\"><span class=\"h1\">TEDIZOLID</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">Tedizolid</a> is an oxazolidinone with activity in vitro against a wide variety of gram-positive organisms, including both methicillin-resistant <em>S. aureus</em> (MRSA) and vancomycin-resistant enterococcus (VRE) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/102\" class=\"abstract_t\">102</a>]. In the absence of available in vitro test results, <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> serves as a reliable surrogate for tedizolid susceptibility testing [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/103\" class=\"abstract_t\">103</a>]. It is US Food and Drug Administration approved for the treatment of adults with acute bacterial skin and skin structure infections caused by susceptible staphylococci, streptococci, and <em>E. faecalis</em>.</p><p class=\"headingAnchor\" id=\"H340582793\"><span class=\"h2\">Mechanism, resistance, and pharmacodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">Tedizolid</a> binds to the 23S ribosomal RNA of the 50S subunit, resulting in inhibition of bacterial protein synthesis. It is considered bacteriostatic against enterococci, staphylococci, and streptococci [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/104\" class=\"abstract_t\">104</a>]. Isolates exhibiting elevated tedizolid minimum inhibitory concentration values generally either carry the <em>cfr</em> multidrug-resistance gene or exhibit mutations in the genes encoding 23S rRNA or those encoding ribosomal proteins L3 or L4 and 5 [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/105\" class=\"abstract_t\">105</a>].</p><p>Based on data from animal models, activity correlates best with area under the time-concentration curve to minimum inhibitory concentration ratio [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/106\" class=\"abstract_t\">106</a>].</p><p>Animal model data suggest that <a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">tedizolid</a>'s activity may be reduced in the setting of granulocytopenia, making its appropriate use in patients with low white blood cell count questionable [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/106\" class=\"abstract_t\">106</a>].</p><p class=\"headingAnchor\" id=\"H929709809\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">Tedizolid</a> phosphate is an inactive prodrug converted by serum phosphatases to the active form, tedizolid. It exhibits excellent bioavailability (91 percent) after oral administration. Protein binding ranges from 70 to 90 percent and, based on the large volume of distribution (ranging from 67 to 80 L following a single dose), it is extensively distributed. Approximately 80 percent and 20 percent of the dose is recovered in feces and urine, respectively, as an inactive metabolite. The half-life is approximately 12 hours [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/106,107\" class=\"abstract_t\">106,107</a>]. The pharmacokinetics of tedizolid following a single 200 mg dose in adolescents 12 to 17 years of age was very similar to that in adults [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/108\" class=\"abstract_t\">108</a>].</p><p class=\"headingAnchor\" id=\"H1109703099\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of adverse effects are gastrointestinal (such as nausea, vomiting, and diarrhea). Hematologic toxicity (most notably thrombocytopenia) appears to be significantly lower than that observed with <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/109\" class=\"abstract_t\">109</a>]. Thrombocytopenia at days 11 to 13 were 4.9 percent and 10.8 percent in tedizolid- and linezolid-treated patients, respectively. These data are likely influenced by the different durations of therapy (6 versus 10 days, respectively).</p><p class=\"headingAnchor\" id=\"H3181915815\"><span class=\"h2\">Use in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no adequate and well-controlled studies in pregnant women. In animal models, <a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">tedizolid</a> phosphate has produced fetal developmental toxicities. No adverse maternal or offspring effects were reported with pre- or postnatal exposure comparable to human exposure following usual doses.</p><p class=\"headingAnchor\" id=\"H497242074\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">Tedizolid</a> is a reversible inhibitor of monoamine oxidase in vitro [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/110\" class=\"abstract_t\">110</a>]. Potential drug interactions resulting from such activity (such as interactions with select serotonin reuptake inhibitors [SSRIs] and others) have not been evaluated in clinical trials. In theory, such effects might occur less frequently with tedizolid than <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>, due (in part) to the differing pharmacokinetic profiles of these agents.</p><p class=\"headingAnchor\" id=\"H19053993\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The adult dose of <a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">tedizolid</a> for its approved indication is 200 mg (by mouth or intravenously) once daily for six days. No dose adjustments are needed in patients with hepatic <span class=\"nowrap\">and/or</span> renal impairment nor in those undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/111\" class=\"abstract_t\">111</a>].</p><p class=\"headingAnchor\" id=\"H2254848824\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Monitoring of complete blood counts may be advisable, although the incidence of cytopenia with short-term use is low.</p><p class=\"headingAnchor\" id=\"H13032953\"><span class=\"h1\">CEFTAROLINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">Ceftaroline</a> is a parenteral cephalosporin with antimicrobial activity against <em>S. aureus</em> (including methicillin-resistant <em>S. aureus</em> [MRSA], vancomycin-intermediate <em>S. aureus</em>, and vancomycin-resistant <em>S. aureus</em>) and vancomycin-susceptible and vancomycin-resistant <em>E. faecalis</em> due to VanA [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/112,113\" class=\"abstract_t\">112,113</a>]. In addition to its gram-positive activity, ceftaroline has in vitro activity against gram-negative respiratory pathogens, such as <em>Moraxella catarrhalis</em> and <em>Haemophilus influenzae</em> (including beta-lactamase&ndash;positive strains). Its in vitro activity against gram-negative organisms is comparable to that of <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a>.</p><p><a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">Ceftaroline</a> is approved by the US Food and Drug Administration (FDA) for treatment of adult and pediatric patients with complicated skin and skin structure infections (inclusive of MRSA) and community-acquired bacterial pneumonia (not including those caused by MRSA). There are increasing reports of the use of ceftaroline for a variety of other invasive MRSA infections [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/114-117\" class=\"abstract_t\">114-117</a>].</p><p class=\"headingAnchor\" id=\"H13032961\"><span class=\"h2\">Mechanism and pharmacodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">Ceftaroline</a> binds to penicillin-binding proteins (PBPs); it has enhanced affinity for PBP subclasses 1, 2, and 3. In addition, it has activity against MRSA (PBP 2a) and multidrug-resistant <em>S. pneumoniae</em> (PBP 1a, 2b, and 2x). MRSA strains with a single <em>mecA</em> mutation (E447K) may express low-level resistance, while mutations in <em>pbp2</em>, <em>pbp4</em>, and <em>gdpP </em>(but not <em>mecA</em>) confer high-level ceftaroline resistance [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/118\" class=\"abstract_t\">118</a>].</p><p>In patients with acute bacterial skin and skin structure infections due to <em>S. aureus</em>, a significant relationship has been observed between the time of free fraction of drug over the minimum inhibitory concentration and microbiological response [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/119\" class=\"abstract_t\">119</a>].</p><p class=\"headingAnchor\" id=\"H13032969\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The inactive prodrug <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> fosamil is administered by intravenous infusion and rapidly undergoes biotransformation to ceftaroline. Ceftaroline then follows a two-compartment pharmacokinetic model and is eliminated primarily by renal excretion with a half-life of approximately 2.5 hours.</p><p>Tissue penetration is similar to that of other cephalosporins and beta-lactams; less than 20 percent of <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> is bound to plasma proteins [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/120\" class=\"abstract_t\">120</a>]. Animal studies have suggested good bone and joint penetration and achieved significant reductions of MRSA colony counts compared with controls; colony reductions were comparable with those of <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> and <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/121\" class=\"abstract_t\">121</a>]. Cerebrospinal fluid penetration of ceftaroline into inflamed meninges was 15 percent in rabbit meningitis models [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/122\" class=\"abstract_t\">122</a>].</p><p>Time above the minimum inhibitory concentration is the pharmacodynamic parameter that best predicts efficacy for <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>. Ceftaroline has a brief postantibiotic effect following a single infusion, which may last as long as 7.2 hours for <em>S. aureus</em> based on in vitro studies [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/123\" class=\"abstract_t\">123</a>].</p><p class=\"headingAnchor\" id=\"H13032977\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The dose of <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> approved by the FDA in adults is 600 mg intravenously twice daily. Pediatric dosing is based on patient age and weight as follows [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/124\" class=\"abstract_t\">124</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>2 years to &lt;18 years &le;33 kg: 12 <span class=\"nowrap\">mg/kg</span> every 8 hours</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>2 years to &lt;18 years &gt;33 kg: 400 mg every 8 hours or 600 mg every 12 hours</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>2 months to &lt;2 years: 8 <span class=\"nowrap\">mg/kg</span> every 8 hours</p><p/><p>Dose adjustment is warranted for patients with renal impairment. For adult patients with creatinine clearance &gt;30 to &le;50, dosing is 400 mg intravenously (IV; over 1 hour) every 12 hours; for patients with creatinine clearance &ge;15 to &le;30, dosing is 300 mg IV (over 1 hour) every 12 hours. For patients with end-stage renal disease, including those undergoing hemodialysis, dosing is 200 mg IV (over 1 hour) every 12 hours.</p><p>Higher (non-FDA-approved) doses of <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> have been reported in the treatment of refractory, invasive MRSA infections (such as meningitis and endocarditis). Doses up to (and in some cases exceeding) 600 mg IV every eight hours have been used in such settings [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/114-117,125,126\" class=\"abstract_t\">114-117,125,126</a>]. One <span class=\"nowrap\">pharmacokinetics/pharmacodynamics</span> study utilizing data from patients with community-acquired bacterial pneumonia and complicated skin and skin structure infections supported ceftaroline dosing of 600 mg IV every eight hours (administered as a two-hour infusion) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/127\" class=\"abstract_t\">127</a>].</p><p>Limited studies in both children [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/128\" class=\"abstract_t\">128</a>] and adults [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/129\" class=\"abstract_t\">129</a>] with cystic fibrosis indicate enhanced clearance of <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> in these patients and the need for consideration of increasing the number of administrations per day.</p><p class=\"headingAnchor\" id=\"H13032985\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">Ceftaroline</a> is generally well tolerated. The most common adverse events in phase III studies were diarrhea (4 percent), headache (3 percent), and insomnia (3 percent). The incidence of these events was not higher than those in the comparator <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> group [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/130\" class=\"abstract_t\">130</a>]. The rate of drug discontinuation was similar between the groups (4 to 5 percent) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/130\" class=\"abstract_t\">130</a>]. A seroconversion of direct Coombs' test (in the absence of hemolytic anemia) has been reported with ceftaroline in up to 10 percent of adults and in 17 to 26 percent of children [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/131,132\" class=\"abstract_t\">131,132</a>].</p><p>Neutropenia has been reported in up to 10 percent of patients receiving <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/133\" class=\"abstract_t\">133</a>]. The incidence of such a reaction appears to be related to the duration of therapy.</p><p class=\"headingAnchor\" id=\"H13032993\"><span class=\"h2\">Use in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No well-controlled studies with <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> in pregnant women have been performed. There is no evidence of teratogenic effects in animal studies.</p><p class=\"headingAnchor\" id=\"H13033001\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No clinical drug interaction studies have been conducted with <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>. In the clinical studies including patients taking concurrent drugs known to be cytochrome P450 enzyme inducers, inhibitors, or substrates, no clinically relevant differences in ceftaroline exposure were observed [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/134\" class=\"abstract_t\">134</a>].</p><p class=\"headingAnchor\" id=\"H681949725\"><span class=\"h1\">TELAVANCIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">Telavancin</a> is a synthetic lipoglycopeptide with in vitro activity against most gram-positive organisms, including methicillin-resistant <em>S. aureus </em>(MRSA) and enterococcus. It is US Food and Drug Administration (FDA) approved for treatment of adult patients with complicated skin and skin structure infections and nosocomial pneumonia (hospital-acquired and ventilator-associated) caused by <em>S. aureus</em> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/135,136\" class=\"abstract_t\">135,136</a>]. Limited clinical data have also been published in patients with uncomplicated <em>S. aureus</em> bacteremia.</p><p><a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">Telavancin</a> has potent activity in vitro against vancomycin-sensitive enterococci (<em>E. faecalis</em> and <em>E. faecium</em>). Minimum inhibitory concentrations (MICs) are significantly increased against vancomycin-resistant enterococci (VRE) strains (most notably in VanA phenotype strains of <em>E. faecium</em>) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/137,138\" class=\"abstract_t\">137,138</a>]. Telavancin (similar to other glycopeptides but perhaps by different mechanisms) demonstrates stepwise selection of isolates with elevated MICs (four- to eightfold) in <em>E. faecalis</em> and <em>E. faecium </em>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/139\" class=\"abstract_t\">139</a>]. Published clinical data to support the use of telavancin in the treatment of VRE infections are lacking [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/140\" class=\"abstract_t\">140</a>].</p><p class=\"headingAnchor\" id=\"H681949617\"><span class=\"h2\">Mechanism and pharmacodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">Telavancin</a> inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane barrier functions. The result is concentration-dependent, bactericidal activity. Telavancin's postantibiotic effect for most gram-positive organisms ranges from one to six hours [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/141\" class=\"abstract_t\">141</a>].</p><p class=\"headingAnchor\" id=\"H681949623\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">Telavancin</a> displays linear kinetics after intravenous (IV) administration. It is highly protein bound (&gt;90 percent) with a volume of distribution of 0.1 to 0.13 <span class=\"nowrap\">L/kg</span> at steady state. Telavancin does not undergo hepatic metabolism. Approximately 76 percent of the dose is excreted in the urine and &lt;1 percent in stool [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/142\" class=\"abstract_t\">142</a>]. Serum concentrations are significantly higher in subjects with moderate to severe renal impairment.</p><p class=\"headingAnchor\" id=\"H681949629\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infusion-related reactions (similar to red man syndrome with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>) can occur with rapid intravenous infusions and are generally managed by stopping or slowing the infusion rate. Taste disturbances and foamy urine were reported in &gt;10 percent of patients participating in registry studies [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/143\" class=\"abstract_t\">143</a>].</p><p><a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">Telavancin</a> has been associated with QT prolongation and should be used with caution in patients at increased risk (such as [but not limited to] those on concomitant medications known to prolong QT interval, congenital prolonged QT syndrome, certain cardiac arrhythmias, and select electrolyte imbalance) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/144\" class=\"abstract_t\">144</a>]. Telavancin has been associated with worsening renal function in 3 to 10 percent of patients. Up to a 1.5-fold increase in serum creatinine above normal baseline has been reported in approximately 15 percent of patients treated with telavancin. Risk factors include underlying renal dysfunction, select comorbidities, and concomitant nephrotoxins. In most cases, renal function returns to baseline after drug discontinuation.</p><p>Increased mortality (relative to the comparator agent <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>) has been reported in patients with nosocomial pneumonia and moderate to severe renal impairment (creatinine clearance &lt;50 <span class=\"nowrap\">mL/min)</span> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/145\" class=\"abstract_t\">145</a>]. Therefore, use in such patients should be restricted to situations where no suitable alternatives are available. In studies evaluating the use of <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a> for complicated skin and skin structure infections, patients with a similar degree of baseline renal dysfunction also exhibited a decreased response to treatment with telavancin.</p><p class=\"headingAnchor\" id=\"H681949731\"><span class=\"h2\">Use in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Animal model data in three species demonstrated uncommon limb and skeletal malformations. Therefore, <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a> should not be used in pregnant patients. Women of childbearing potential should have a negative pregnancy test prior to administration of telavancin.</p><p class=\"headingAnchor\" id=\"H681949635\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><span class=\"nowrap\">Pharmacokinetic/pharmacodynamic</span> drug interactions with <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a> are minimal. Drug-drug interactions result primarily due to the potential for additive toxicity with concurrent or sequential use of agents with potential for QT prolongation or nephrotoxicity.</p><p>Drug-lab interactions with <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a> include prolongation of plasma prothrombin, international normalized ratio, activated partial thromboplastin time (aPTT), activated clotting time, coagulation-based factor Xa tests, and activated partial thromboplastin clotting times in clinical diagnostic lab-based assays [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/146\" class=\"abstract_t\">146</a>].</p><p>Recommendations to minimize the impact of the interaction include monitoring coagulation immediately prior to the next <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a> dose. A non-phospholipid-dependent coagulation test (such as chromogenic factor Xa) assay or an alternative anticoagulant not requiring aPTT monitoring should be considered in patients requiring anticoagulant monitoring during concomitant telavancin administration. Telavancin may interfere with urine qualitative dipstick protein assays and quantitative dye methods. It does not interfere with microalbumin assays.</p><p class=\"headingAnchor\" id=\"H681949641\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dosing for creatinine clearance &gt;50 <span class=\"nowrap\">mL/min</span> consists of 10 <span class=\"nowrap\">mg/kg</span> intravenously (over 60 minutes) once daily. Dosing for creatinine clearance 30 to 50 <span class=\"nowrap\">mL/min</span> consists of 7.5 <span class=\"nowrap\">mg/kg</span> IV every 24 hours; dosing for creatinine clearance 10 to 29 <span class=\"nowrap\">mL/min</span> consists of 10 <span class=\"nowrap\">mg/kg</span> IV every 48 hours.</p><p class=\"headingAnchor\" id=\"H681949647\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum creatinine should be obtained prior to initiating therapy at two- to three-day intervals during therapy and after treatment discontinuation. Patients should be observed for infusion-related reactions (which may be manifested as upper body flushing pruritus) <span class=\"nowrap\">and/or</span> rash, which generally resolve by slowing (over at least one hour) or stopping the infusion.</p><p class=\"headingAnchor\" id=\"H681949737\"><span class=\"h1\">DALBAVANCIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> is a lipoglycopeptide that the US Food and Drug Administration approved for treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive pathogens (including [but not limited to] methicillin-susceptible and methicillin-resistant <em>S. aureus </em>and streptococci). Limited published data exist for more serious (invasive) staphylococcal infections. In one open-label randomized trial among adult patients with catheter-related bloodstream infections caused by gram-positive pathogens, an 87 percent treatment success rate was reported in patients receiving dalbavancin [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/147\" class=\"abstract_t\">147</a>].</p><p>Case reports describe the clinical application of <a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">dalbavancin</a> (both successful and unsuccessful) in the treatment of staphylococcal infections such as pneumonia, endocarditis, and prosthetic joint infections. Data regarding the use of dalbavancin in pediatric patients have been summarized [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/148\" class=\"abstract_t\">148</a>].</p><p><a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> also has activity in vitro against enterococci (including vancomycin-resistant enterococcus). However, enterococci exhibit elevated minimum inhibitory concentrations (MICs) relative to staphylococci and streptococci. This elevation is most notable in VanA phenotype-resistant <em>E. faecalis </em>or <em>E. faecium </em>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/149\" class=\"abstract_t\">149</a>]. In addition, dalbavancin (similar to other glycopeptides but perhaps by different mechanisms) demonstrates stepwise selection of isolates with elevated MICs (4- to &gt;128-fold) in <em>E. faecalis</em> and <em>E. faecium </em>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/139\" class=\"abstract_t\">139</a>].</p><p class=\"headingAnchor\" id=\"H681949653\"><span class=\"h2\">Mechanism and pharmacodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> binds to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, preventing cross-linking and interfering with cell wall synthesis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/150\" class=\"abstract_t\">150</a>]. It is bactericidal in vitro against <em>S. aureus</em> and <em>Streptococcus pyogenes </em>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/150,151\" class=\"abstract_t\">150,151</a>].</p><p class=\"headingAnchor\" id=\"H681949659\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> is highly protein bound (approximately 93 percent primarily to albumin) and has a terminal half-life of two weeks [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/151\" class=\"abstract_t\">151</a>]. Approximately 20 percent of the dose is excreted in feces and one-third as unchanged drug in the urine [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/150,151\" class=\"abstract_t\">150,151</a>].</p><p class=\"headingAnchor\" id=\"H681949665\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> is generally well tolerated. Side effects noted in clinical trials of ABSSSI have been primarily gastrointestinal (nausea, diarrhea) and headache. There is a possibility of cross-sensitivity with other glycopeptides. Rarely, serious anaphylactic and skin reactions have been reported in patients treated with dalbavancin [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/150,151\" class=\"abstract_t\">150,151</a>]. Infusion-related reactions (similar to the &quot;red man syndrome&quot; reported with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>) have also been observed during dalbavancin administration.</p><p class=\"headingAnchor\" id=\"H681949743\"><span class=\"h2\">Use in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No adequate studies in pregnant women are available for <a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">dalbavancin</a>.</p><p class=\"headingAnchor\" id=\"H681949671\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No clinical drug-drug interaction studies have been conducted. <a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> is not a substrate, inducer, or inhibitor of CYP450, so the potential for interactions via this mechanism is limited.</p><p class=\"headingAnchor\" id=\"H681949677\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dosing for treatment of ABSSSI consists of either a two-dose regimen (1000 mg [infused intravenously over 30 minutes] followed by 500 mg one week later) or a single-dose regimen (1500 mg) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/152\" class=\"abstract_t\">152</a>]. In patients with creatinine clearance &lt;30 <span class=\"nowrap\">mL/min,</span> dosing consists of 750 mg intravenously followed by 375 mg one week later [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/150\" class=\"abstract_t\">150</a>]. No dosing adjustments are required in patients receiving hemodialysis.</p><p>Limited data are available regarding the pharmacokinetic profile in pediatric patients. Data from an open-label, phase I trial of a single dose of intravenous <a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">dalbavancin</a> in hospitalized patients 3 months to 11 years was combined with prior data to determine pediatric dosing recommendations [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/153\" class=\"abstract_t\">153</a>].<em> </em>Day 1<em> </em>dosing to provide exposures similar to adults receiving a single 1500 mg IV dose were as follows: 6 to &lt;18 years of age would receive 18 <span class=\"nowrap\">mg/kg</span> (1500 mg maximum), and 3 months to &lt;6 years of age would receive 22.5 <span class=\"nowrap\">mg/kg</span> (1500 mg maximum). Exposures comparable to adults receiving the two-dose regimen were as follows: children 6 to &lt;18 years of age, 12 <span class=\"nowrap\">mg/kg</span> (1000 mg maximum) on day 1 and 6 <span class=\"nowrap\">mg/kg</span> (500 mg maximum) on day 8, and children 3 months to &lt;6 years of age, 15 <span class=\"nowrap\">mg/kg</span> (1000 mg maximum) on day 1 and 7.5 <span class=\"nowrap\">mg/kg</span> (500 mg maximum) on day 8.</p><p class=\"headingAnchor\" id=\"H681949683\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients should be monitored for infusion-related reactions, which generally resolve by prolonging (&gt;30 minute) or discontinuing the infusion.</p><p class=\"headingAnchor\" id=\"H681949749\"><span class=\"h1\">ORITAVANCIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">Oritavancin</a> is a lipoglycopeptide approved by the US Food and Drug Administration for treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive pathogens (including [but not limited to] methicillin-susceptible and methicillin-resistant <em>S. aureus</em> and streptococci and vancomycin-susceptible <em>E. faecalis</em>) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/154\" class=\"abstract_t\">154</a>]. Case reports have described the use of oritavancin for other invasive gram-positive infections [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/155\" class=\"abstract_t\">155</a>].</p><p>Vancomycin-nonsusceptible enterococci are often susceptible to <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/156\" class=\"abstract_t\">156</a>]. Oritavancin exhibits potent activity in vitro against both vancomycin-susceptible and <em>vanB</em>-carrying <em>E. faecalis</em> isolates; higher minimum inhibitory concentrations (up to 16- to 32-fold) for <em>vanA</em>-harboring <em>E. faecalis</em> have been observed [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/157\" class=\"abstract_t\">157</a>].</p><p class=\"headingAnchor\" id=\"H681949689\"><span class=\"h2\">Mechanism and pharmacodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">Oritavancin</a> inhibits bacterial cell wall synthesis in many gram-positive bacteria. Its bactericidal activity is concentration dependent and best predicted by the area under the concentration-time curve to minimal inhibitory concentration ratio [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/154\" class=\"abstract_t\">154</a>].</p><p><a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">Oritavancin</a> demonstrated bactericidal activity against three VanA VR <em>E. faecium</em> isolates in an in vitro study following a single dose [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/158\" class=\"abstract_t\">158</a>].<em> </em>Oritavancin (similar to other glycopeptides but perhaps by different mechanisms) demonstrates stepwise selection of isolates with elevated minimum inhibitory concentrations (4- to 32-fold) in <em>E. faecalis</em> and <em>E. faecium </em>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/139\" class=\"abstract_t\">139</a>].</p><p class=\"headingAnchor\" id=\"H681949695\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">Oritavancin</a> is highly protein bound (85 percent) and widely distributed. It is slowly excreted unchanged in the stool and urine with a half-life of approximately 245 hours [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/154,159\" class=\"abstract_t\">154,159</a>].</p><p class=\"headingAnchor\" id=\"H681949701\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">Oritavancin</a> is generally well tolerated. Adverse reactions may include gastrointestinal symptoms (nausea, vomiting, diarrhea), headache, and infusion-related reactions. Hypersensitivity reactions are infrequent [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/154\" class=\"abstract_t\">154</a>].</p><p class=\"headingAnchor\" id=\"H681949707\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients receiving <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a> require careful interpretation of coagulation tests. Oritavancin may artificially prolong activated partial thromboplastin time (aPTT) for up to 5 days, may prolong prothrombin time (PT) and international normalized ratio (INR) for up to 12 hours, and may prolong activated whole-blood clotting time (ACT) for up to 24 hours [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/160\" class=\"abstract_t\">160</a>]. For patients who require aPTT monitoring within 120 hours of oritavancin administration, a non-phospholipid-dependent coagulation test (such as a Factor Xa assay) may be used; alternatively, an anticoagulant not requiring aPTT may be used.</p><p><a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">Oritavancin</a> is a weak inducer of CYP3A4 and CYP2D6 and a weak inhibitor of CYP2C9 and CYP2C19 [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/154\" class=\"abstract_t\">154</a>].</p><p class=\"headingAnchor\" id=\"H681949713\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A single 1200 mg dose infused intravenously over three hours is used for treatment of ABSSSI in adults. No dose adjustment is required for mild to moderate renal impairment. The clearance of <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a> in patients with a creatinine clearance &lt;30 <span class=\"nowrap\">mL/min</span> has not been evaluated [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/154\" class=\"abstract_t\">154</a>].</p><p class=\"headingAnchor\" id=\"H681949719\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infusion-related reactions should be managed by slowing of the infusion rate [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/154\" class=\"abstract_t\">154</a>]. Patients receiving concomitant <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> should be monitored for bleeding.</p><p class=\"headingAnchor\" id=\"H931305133\"><span class=\"h1\">TIGECYCLINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">Tigecycline</a> is a glycylcycline antibiotic with in vitro activities against a variety of gram-positive organisms, including methicillin-sensitive <em>S. aureus</em>, methicillin-resistant <em>S. aureus</em>, and <em>E. faecalis</em> (including vancomycin-resistant variants) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/161-164\" class=\"abstract_t\">161-164</a>]. In addition, tigecycline exhibits activity against a broad spectrum of gram-negative and anaerobic organisms. Notable exceptions are the lack of activity against <em>Pseudomonas</em> spp and <em>Proteus </em>spp [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/165\" class=\"abstract_t\">165</a>]. Tigecycline is US Food and Drug Administration (FDA) approved for complicated skin and skin structure infections, complicated intraabdominal infections, and community-acquired pneumonia.</p><p class=\"headingAnchor\" id=\"H931305240\"><span class=\"h2\">Mechanism and pharmacodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">Tigecycline</a> inhibits bacterial protein synthesis by acting on the 30S ribosomal subunit and preventing amino acids from becoming incorporated into elongating peptide chains [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/166,167\" class=\"abstract_t\">166,167</a>]. Tigecycline is bacteriostatic and has prolonged postantibiotic effect [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/168,169\" class=\"abstract_t\">168,169</a>]. It appears to have both time- and concentration-dependent characteristics, and its antimicrobial effect correlates well with the area under the time-concentration curve achieved by the drug [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/170\" class=\"abstract_t\">170</a>].</p><p><em>Pseudomonas</em> spp and <em>Proteus </em>spp have intrinsic resistance to <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>. The reduced susceptibility to tigecycline in gram-negative organisms is largely mediated by multidrug efflux pumps [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/171\" class=\"abstract_t\">171</a>].</p><p class=\"headingAnchor\" id=\"H931305326\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">Tigecycline</a> has poor bioavailability from the gastrointestinal tract and requires intravenous administration. Tigecycline binds moderately to plasma proteins (68 percent), distributes extensively into tissues, and (consequently) has low serum drug concentrations [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/172,173\" class=\"abstract_t\">172,173</a>]. Tissue drug concentrations in humans vary widely. Tigecycline adequately penetrates into the alveolar epithelial cells and the biliary tract, but entry into bone and synovial membranes is poor [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/174,175\" class=\"abstract_t\">174,175</a>]. Cerebrospinal fluid penetration through uninflamed meninges is also minimal, and it is uncertain whether tigecycline is adequate for reliable treatment of meningitis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/174-176\" class=\"abstract_t\">174-176</a>].</p><p><a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">Tigecycline</a> is eliminated by glucuronidation and subsequent excretion via the biliary tract. Less than 30 percent of the drug is excreted in the urine [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/177\" class=\"abstract_t\">177</a>].</p><p class=\"headingAnchor\" id=\"H931305440\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common adverse drug effects reported in phase III studies of <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a> were mild nausea and vomiting (approximately 30 and 19 percent of patients, respectively) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/178\" class=\"abstract_t\">178</a>]. In one pediatric study, 50 percent of children receiving tigecycline experienced nausea [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/179\" class=\"abstract_t\">179</a>]. Tigecycline, like its relatives in the <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> family, carries the potential for discoloring dentition and fetal teratogenicity [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/165\" class=\"abstract_t\">165</a>]. Animal studies showed that tigecycline crossed the placenta and was detected in fetal tissue, including fetal bony structures.</p><p>In September 2013, the FDA added a boxed warning to the label of <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a> due to the increased risk for death observed in patients receiving the drug [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/180\" class=\"abstract_t\">180</a>]. The decision was based primarily on a meta-analysis of 13 clinical trials for which tigecycline was evaluated for both approved and unapproved (ie, hospital-acquired pneumonia, diabetic foot infections) indications [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/181\" class=\"abstract_t\">181</a>]. The FDA recommends its use be restricted to situations where other antibiotics are unsuitable.</p><p class=\"headingAnchor\" id=\"H931305502\"><span class=\"h2\">Use in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An animal study also showed delayed bone and increased incidence of fetal loss [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/182\" class=\"abstract_t\">182</a>]. Therefore, <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a> should not be used in pregnancy unless the potential benefit clearly outweighs the potential risk to the mother or the fetus [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/182\" class=\"abstract_t\">182</a>].</p><p class=\"headingAnchor\" id=\"H931305536\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">Tigecycline</a> may decrease the elimination of <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/183\" class=\"abstract_t\">183</a>]. Patients receiving anticoagulation with warfarin should have the international normalized ratio (INR) monitored closely with adjustment in dosing as needed.</p><p class=\"headingAnchor\" id=\"H931305556\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Administration of <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a> consists of a single loading dose of 100 mg intravenously (IV) followed by 50 mg IV every 12 hours. One potential strategy to optimize its pharmacodynamic properties (primarily directed at treatment of multidrug-resistant gram-negative rods), consists of increasing the dose (ie, 200 to 400 mg once, then 100 to 200 mg every 24 hours); this approach requires further study [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/184\" class=\"abstract_t\">184</a>]. The dose of tigecycline in children 8 to 11 years of age is 1.2 <span class=\"nowrap\">mg/kg/dose</span> (up to 50 mg) every 12 hours.</p><p>Maintenance doses should be reduced by one-half in patients with severe hepatic dysfunction (Child-Pugh C). No dosage adjustment is required for patients with renal impairment or hemodialysis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/177\" class=\"abstract_t\">177</a>].</p><p class=\"headingAnchor\" id=\"H931305576\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">Tigecycline</a> does not require routine laboratory or serum concentration monitoring. Patients with hepatic dysfunction should have liver function tests taken at the baseline and regularly throughout the treatment with tigecycline. Patients receiving anticoagulation with <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> should have the INR monitored closely with adjustment in dosing as needed.</p><p class=\"headingAnchor\" id=\"H931303774\"><span class=\"h1\">QUINUPRISTIN-DALFOPRISTIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">Quinupristin-dalfopristin</a> (QD) is a combination of two semisynthetic streptogramins in a ratio of 30:70 [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/185\" class=\"abstract_t\">185</a>]. QD has activity in vitro against gram-positive organisms including methicillin-sensitive <em>S. aureus</em> and methicillin-resistant <em>S. aureus</em> (MRSA). QD is active against <em>E. faecium</em> but not <em>E. faecalis</em> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/186\" class=\"abstract_t\">186</a>].</p><p class=\"headingAnchor\" id=\"H931303833\"><span class=\"h2\">Mechanism and pharmacodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">Quinupristin-dalfopristin</a> binds to two sequential sites on the 50S subunit of the bacterial ribosome, resulting in a conformational change in the ribosome and preventing protein synthesis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/187\" class=\"abstract_t\">187</a>]. QD is a concentration-dependent bactericidal antibiotic [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/188\" class=\"abstract_t\">188</a>]. Staphylococcal isolates constitutively expressing macrolide-lincosamide-streptogramin B resistance (eg, <em>ermA</em> or <em>ermC</em>) may be resistant to the quinupristin component of QD. In such cases, the activity of QD may be significantly altered and become bacteriostatic [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/189,190\" class=\"abstract_t\">189,190</a>].</p><p><a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">Quinupristin-dalfopristin</a> is a mixture of two synergistic streptogramins; each component of QD is associated with different mechanisms of resistance [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/191\" class=\"abstract_t\">191</a>]. Resistant staphylococci are more likely to have resistance to the dalfopristin component due to genes encoding acetyltransferases (<em>vatA</em>, <em>vatB</em>, and <em>vatC</em>) or efflux pumps (<em>vgaA</em> and <em>vgaB</em>) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/192-195\" class=\"abstract_t\">192-195</a>]. Resistance to the quinupristin component occurs as a result of production of ribosomal methylases encoded by <em>erm</em> genes or the macrolide-lincosamide-streptogramin B phenotype (which also confers cross-resistance to macrolides and lincosamides).</p><p class=\"headingAnchor\" id=\"H931303969\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The two components of QD have different affinity for serum protein: approximately 30 percent of quinupristin and 50 percent of dalfopristin are protein bound [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/187\" class=\"abstract_t\">187</a>]. After intravenous administration, <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a> penetrates readily into intraabdominal organs such as kidneys, liver, and the spleen [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/196\" class=\"abstract_t\">196</a>]. Penetration of QD into other tissues varies significantly. Studies on lung tissue penetration have shown variable results; clinical studies appear to demonstrate efficacy for treatment of pneumonia [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/197\" class=\"abstract_t\">197</a>]. Minimal data exist regarding penetration of QD into bones and joints; limited clinical data appear to demonstrate efficacy against infections at these sites [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/198\" class=\"abstract_t\">198</a>]. Quinupristin-dalfopristin penetrates poorly into the central nervous system (CNS) and should not be used as monotherapy for CNS infections [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/196\" class=\"abstract_t\">196</a>].</p><p>QD undergoes hepatic metabolism to produce several active metabolites that are primarily eliminated in the feces [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/196\" class=\"abstract_t\">196</a>].</p><p class=\"headingAnchor\" id=\"H931304059\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>QD frequently causes infusion site pain and edema (50 to 75 percent) and occasionally thrombophlebitis (2 percent) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/199\" class=\"abstract_t\">199</a>]. Other adverse effects associated with QD include nausea and myalgias [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/200,201\" class=\"abstract_t\">200,201</a>]. The severity of these adverse effects in clinical trials prompted discontinuation of treatment with QD in 15 to 19 percent of patients [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/188\" class=\"abstract_t\">188</a>].</p><p>QD is associated with increased levels of total and conjugated bilirubin; increases &gt;5 times the upper limit of normal occurred in approximately 30 percent of recipients [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/202\" class=\"abstract_t\">202</a>]. The clinical importance of the hyperbilirubinemia is uncertain as many patients enrolled in studies had high baseline bilirubin levels. Transient elevations in transaminases and alkaline phosphatase were also noted.</p><p class=\"headingAnchor\" id=\"H931304133\"><span class=\"h2\">Use in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no evidence of teratogenic effects in animal studies. There are no adequate or well-controlled studies with QD in pregnant women.</p><p class=\"headingAnchor\" id=\"H931304139\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">Quinupristin-dalfopristin</a> is a potent inhibitor of the CYP3A4 isoenzyme and may increase the pharmacologic action of other medications that are metabolized via this pathway [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/199\" class=\"abstract_t\">199</a>]. For example, coadministration with <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, antiretroviral agents, calcium channel blockers, statins, and anticonvulsants can result in significant changes in the serum level and half-life of these drugs. Coadministration of QD with any agent that is metabolized via this enzymatic pathway should be closely monitored.</p><p class=\"headingAnchor\" id=\"H931304159\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual dose of QD for MRSA soft tissue infections is 7.5 <span class=\"nowrap\">mg/kg</span> every 12 hours intravenously; vancomycin-resistant enterococcus (<em>E. faecium</em>) infections are treated with 7.5 <span class=\"nowrap\">mg/kg</span> every 8 hours.</p><p>QD should be infused through a central venous catheter over one hour due to the substantial risk of local pain and thrombophlebitis. The concomitant use of <a href=\"topic.htm?path=hydrocortisone-drug-information\" class=\"drug drug_general\">hydrocortisone</a> or <a href=\"topic.htm?path=diphenhydramine-drug-information\" class=\"drug drug_general\">diphenhydramine</a> does not alleviate venous pain or inflammation [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/188\" class=\"abstract_t\">188</a>]. If irritation occurs after peripheral administration, interventions may include changing the infusion volume or the infusion site or infusing by a peripherally inserted central catheter or a central venous catheter [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/188\" class=\"abstract_t\">188</a>].</p><p>Dose adjustment is not necessary for patients with renal impairment, as QD is not removed by hemodialysis. Dose adjustment of QD is not required for mild to moderate hepatic impairment (Childs-Pugh class A and B). There are insufficient data to recommend dose adjustment of QD in patients with severe hepatic dysfunction.</p><p class=\"headingAnchor\" id=\"H931304193\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Liver function tests should be performed regularly to assess for elevations in bilirubin and transaminases. Moreover, concurrent use of <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a> and other agents metabolized via cytochrome P450 pathway requires caution and monitoring of these agents where possible (eg, measuring serum <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> levels).</p><p class=\"headingAnchor\" id=\"H34\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> is a bactericidal cyclic lipopeptide with lipophilic tail that inserts itself into the bacterial membrane and forms a channel causing efflux of intracellular potassium, with subsequent depolarization of the cell membrane. Daptomycin administration has been associated with myopathy; weekly creatine phosphokinase monitoring should be performed for prolonged administration. (See <a href=\"#H13034132\" class=\"local\">'Daptomycin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> is a bacteriostatic oxazolidinone that binds to the 50S subunit of the bacterial ribosome, inhibiting bacterial protein synthesis. Important adverse effects related to linezolid use include myelosuppression, optic neuropathy, peripheral neuropathy, lactic acidosis, and serotonin syndrome. Weekly complete blood count monitoring should be performed for prolonged administration. (See <a href=\"#H2\" class=\"local\">'Linezolid'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">Ceftaroline</a> is a parenteral cephalosporin with activity against methicillin-resistant <em>Staphylococcus aureus</em> (MRSA). It is well-tolerated and approved for use in community-acquired pneumonia and for the treatment of complex skin and soft tissue infections, including MRSA. (See <a href=\"#H13032953\" class=\"local\">'Ceftaroline'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">Telavancin</a> is a synthetic lipoglycopeptide with in vitro activity against most gram-positive organisms. Clinical data support its use in select staphylococcal infections (specifically uncomplicated bacteremia, nosocomial pneumonia, and complicated skin and skin structure infections) but are lacking for use in vancomycin-resistant enterococci infection. Safety concerns include infusion-related reactions and nephrotoxicity. (See <a href=\"#H681949725\" class=\"local\">'Telavancin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> is a lipoglycopeptide approved for treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive pathogens (including methicillin-susceptible and methicillin-resistant <em>S. aureus</em> and streptococci). Dalbavancin is highly protein bound and has a terminal half-life of two weeks. Administration of dalbavancin is generally well tolerated. Side effects noted in clinical trials of acute bacterial skin and skin structure infections have been primarily gastrointestinal (nausea, diarrhea) and headache. (See <a href=\"#H681949737\" class=\"local\">'Dalbavancin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">Oritavancin</a> is a lipoglycopeptide approved for treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive pathogens, including methicillin-susceptible and methicillin-resistant <em>S. aureus</em> and streptococci. Vancomycin-nonsusceptible enterococci are often susceptible to oritavancin. Adverse reactions may include gastrointestinal disturbances and headache. Use of heparin for 48 hours after oritavancin administration is contraindicated. A single intravenous dose is used in adult patients for the treatment of acute bacterial skin and skin structure infections. (See <a href=\"#H681949749\" class=\"local\">'Oritavancin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">Tedizolid</a> is an oxazolidinone approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible staphylococci, streptococci, and <em>Enterococcus faecalis</em>. Adverse effects are largely gastrointestinal. Tedizolid is a reversible inhibitor of monoamine oxidase in vitro. (See <a href=\"#H1402177436\" class=\"local\">'Tedizolid'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">Tigecycline</a> is a bacteriostatic glycylcycline active against gram-positive, gram-negative, and anaerobic organisms; it is not active against <em>Pseudomonas</em> or <em>Proteus</em> spp. The most common adverse drug effects are mild nausea and vomiting. The drug's boxed warning, added due to concerns of increased mortality in patients receiving the drug, significantly limits its use for the treatment of gram-positive infections. Its primary application is treatment of multidrug-resistant gram-negative pathogens. (See <a href=\"#H931305133\" class=\"local\">'Tigecycline'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">Quinupristin-dalfopristin</a> is a bactericidal combination of two semisynthetic streptogramins. It must be infused through a central venous catheter due to risk of thrombophlebitis. It is associated with conjugated hyperbilirubinemia; liver function test monitoring should be performed. Use of quinupristin-dalfopristin (most notably for MRSA infections) has been largely supplanted by newer treatment options. (See <a href=\"#H931303774\" class=\"local\">'Quinupristin-dalfopristin'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H2491130045\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Luke Chen, MBBS, MPH, CIC, FRACP, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/1\" class=\"nounderline abstract_t\">Wootton M, MacGowan AP, Walsh TR. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006; 50:4195.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/2\" class=\"nounderline abstract_t\">Dandekar PK, Tessier PR, Williams P, et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003; 52:405.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/3\" class=\"nounderline abstract_t\">Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/4\" class=\"nounderline abstract_t\">Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother 2014; 58:672.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/5\" class=\"nounderline abstract_t\">Claeys KC, Zasowski EJ, Casapao AM, et al. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother 2016; 60:5841.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/6\" class=\"nounderline abstract_t\">Moise PA, Culshaw DL, Wong-Beringer A, et al. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC &gt;1 mg/L: A Multicenter Evaluation. Clin Ther 2016; 38:16.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/7\" class=\"nounderline abstract_t\">Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.</a></li><li class=\"breakAll\">Daptomycin (Cubicin) Product Information. Merck and Co, Inc; Whitehouse, NJ 9/2017.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/9\" class=\"nounderline abstract_t\">Karageorgos SA, Miligkos M, Dakoutrou M, Tsioutis C. Clinical Effectiveness, Safety Profile, and Pharmacokinetics of Daptomycin in Pediatric Patients: A Systematic Review. J Pediatric Infect Dis Soc 2016; 5:446.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/10\" class=\"nounderline abstract_t\">Namtu KC, Crain JC, Messina AF, et al. Clinical Experience with Daptomycin in Pediatrics. Pharmacotherapy 2017; 37:105.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/11\" class=\"nounderline abstract_t\">Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49:467.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/12\" class=\"nounderline abstract_t\">Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:2538.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/13\" class=\"nounderline abstract_t\">Braga PC, Ricci D, Dal Sasso M. Daptomycin morphostructural damage in Bacillus cereus visualized by atomic force microscopy. J Chemother 2002; 14:336.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/14\" class=\"nounderline abstract_t\">Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48:63.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/15\" class=\"nounderline abstract_t\">Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/16\" class=\"nounderline abstract_t\">Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44:655.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/17\" class=\"nounderline abstract_t\">Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52:269.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/18\" class=\"nounderline abstract_t\">Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:1058.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/19\" class=\"nounderline abstract_t\">Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44:595.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/20\" class=\"nounderline abstract_t\">Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008; 27:433.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/21\" class=\"nounderline abstract_t\">King ST, Usery JB, Holloway K, et al. Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections. J Antimicrob Chemother 2011; 66:2673.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/22\" class=\"nounderline abstract_t\">Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47:1318.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/23\" class=\"nounderline abstract_t\">Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55:283.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/24\" class=\"nounderline abstract_t\">Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/25\" class=\"nounderline abstract_t\">Burns CA. Long-term use of daptomycin for MRSA osteomyelitis and joint infection. Scand J Infect Dis 2008; 40:183.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/26\" class=\"nounderline abstract_t\">Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008; 47:588.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/27\" class=\"nounderline abstract_t\">Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/28\" class=\"nounderline abstract_t\">Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006; 42:e108.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/29\" class=\"nounderline abstract_t\">Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 2006; 57:578.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/30\" class=\"nounderline abstract_t\">Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44:2948.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/31\" class=\"nounderline abstract_t\">Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004; 150:137.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/32\" class=\"nounderline abstract_t\">Veligandla SR, Louie KR, Malesker MA, Smith PW. Muscle pain associated with daptomycin. Ann Pharmacother 2004; 38:1860.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/33\" class=\"nounderline abstract_t\">Echevarria K, Datta P, Cadena J, Lewis JS 2nd. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005; 55:599.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/34\" class=\"nounderline abstract_t\">Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis 2010; 50:737.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/35\" class=\"nounderline abstract_t\">Knoll BM, Spieler PJ, Kubiak DW, Marty FM. Neutropenia associated with prolonged daptomycin use. Clin Infect Dis 2013; 56:1353.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/36\" class=\"nounderline abstract_t\">Webster PS, Oleson FB Jr, Paterson DL, et al. Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results. Blood Coagul Fibrinolysis 2008; 19:32.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/37\" class=\"nounderline abstract_t\">Munita JM, Mishra NN, Alvarez D, et al. Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Clin Infect Dis 2014; 59:1277.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/38\" class=\"nounderline abstract_t\">Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003; 47:1598.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/39\" class=\"nounderline abstract_t\">Chuang YC, Lin HY, Chen PY, et al. Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia. Clin Infect Dis 2017; 64:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/40\" class=\"nounderline abstract_t\">Britt NS, Potter EM, Patel N, Steed ME. Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. Clin Infect Dis 2017; 64:605.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/41\" class=\"nounderline abstract_t\">Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50:1568.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/42\" class=\"nounderline abstract_t\">Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/43\" class=\"nounderline abstract_t\">Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/44\" class=\"nounderline abstract_t\">Wootton M, Howe RA, Walsh TR, et al. In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). J Antimicrob Chemother 2002; 50:760.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/45\" class=\"nounderline abstract_t\">Ballow CH, Jones RN, Biedenbach DJ, North American ZAPS Research Group. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002; 43:75.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/46\" class=\"nounderline abstract_t\">Pfaller MA, Mendes RE, Streit JM, et al. Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015). Antimicrob Agents Chemother 2017; 61.</a></li><li class=\"breakAll\">Linezolid (Zyvox) Product Information. Pharmacia and Upjohn, LLC. New York, NY. 1/2017.</li><li class=\"breakAll\">Food and Drug Administration (FDA). FDA Approves Zyvox, The First Antimicrobial Drug In A New Class. In: FDA Talk Paper, Rockville, MD 2000.</li><li class=\"breakAll\">US Food and Drug Administration. Information for healthcare professionals: Linezolid (marketed as Zyvox). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085249.htm (Accessed January 11, 2010).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/50\" class=\"nounderline abstract_t\">Champney WS, Miller M. Linezolid is a specific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol 2002; 44:350.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/51\" class=\"nounderline abstract_t\">Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006; 42:729.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/52\" class=\"nounderline abstract_t\">Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/53\" class=\"nounderline abstract_t\">Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/54\" class=\"nounderline abstract_t\">Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46:3484.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/55\" class=\"nounderline abstract_t\">MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl 2:ii17.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/56\" class=\"nounderline abstract_t\">Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998; 42:721.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/57\" class=\"nounderline abstract_t\">Besier S, Ludwig A, Zander J, et al. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob Agents Chemother 2008; 52:1570.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/58\" class=\"nounderline abstract_t\">Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/59\" class=\"nounderline abstract_t\">Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50:821.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/60\" class=\"nounderline abstract_t\">Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat 2014; 17:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/61\" class=\"nounderline abstract_t\">Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42:1129.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/62\" class=\"nounderline abstract_t\">Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007; 60:819.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/63\" class=\"nounderline abstract_t\">Thallinger C, Buerger C, Plock N, et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008; 61:173.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/64\" class=\"nounderline abstract_t\">Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50:73.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/65\" class=\"nounderline abstract_t\">Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50:3971.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/66\" class=\"nounderline abstract_t\">Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22:S153.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/67\" class=\"nounderline abstract_t\">French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51 Suppl 2:ii45.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/68\" class=\"nounderline abstract_t\">Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50:1599.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/69\" class=\"nounderline abstract_t\">Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/70\" class=\"nounderline abstract_t\">Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/71\" class=\"nounderline abstract_t\">Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006; 28:345.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/72\" class=\"nounderline abstract_t\">Mateu de Antonio J, Grau S, Morales-Molina JA, Mar&iacute;n-Casino M. Thrombocytopenia and anemia associated with linezolid in patients with kidney failure. Clin Infect Dis 2006; 42:1500; author reply 1501.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/73\" class=\"nounderline abstract_t\">Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/74\" class=\"nounderline abstract_t\">Rao N, Ziran BH, Wagener MM, et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004; 38:1058.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/75\" class=\"nounderline abstract_t\">Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004; 54:832.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/76\" class=\"nounderline abstract_t\">Plachouras D, Giannitsioti E, Athanassia S, et al. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis 2006; 43:e89.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/77\" class=\"nounderline abstract_t\">Meissner HC, Townsend T, Wenman W, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22:S186.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/78\" class=\"nounderline abstract_t\">Legout L, Senneville E, Gomel JJ, et al. Linezolid-induced neuropathy. Clin Infect Dis 2004; 38:767.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/79\" class=\"nounderline abstract_t\">Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37:1389.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/80\" class=\"nounderline abstract_t\">Chao CC, Sun HY, Chang YC, Hsieh ST. Painful neuropathy with skin denervation after prolonged use of linezolid. J Neurol Neurosurg Psychiatry 2008; 79:97.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/81\" class=\"nounderline abstract_t\">Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4:528.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/82\" class=\"nounderline abstract_t\">Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006; 66:595.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/83\" class=\"nounderline abstract_t\">De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/84\" class=\"nounderline abstract_t\">Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med 2003; 348:86.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/85\" class=\"nounderline abstract_t\">Javaheri M, Khurana RN, O'hearn TM, et al. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol 2007; 91:111.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/86\" class=\"nounderline abstract_t\">Zivkovic SA, Lacomis D. Severe sensory neuropathy associated with long-term linezolid use. Neurology 2005; 64:926.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/87\" class=\"nounderline abstract_t\">Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007; 27:1189.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/88\" class=\"nounderline abstract_t\">Wiener M, Guo Y, Patel G, Fries BC. Lactic acidosis after treatment with linezolid. Infection 2007; 35:278.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/89\" class=\"nounderline abstract_t\">Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40:e113.</a></li><li class=\"breakAll\">US Food and Drug Administration. Zyvox label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021130s016,021131s013,021132s014lbl.pdf (Accessed January 11, 2010).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/91\" class=\"nounderline abstract_t\">Antal EJ, Hendershot PE, Batts DH, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001; 41:552.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/92\" class=\"nounderline abstract_t\">Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/93\" class=\"nounderline abstract_t\">Ramsey TD, Lau TT, Ensom MH. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother 2013; 47:543.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/94\" class=\"nounderline abstract_t\">Marcucci C, Sandson NB, Dunlap JA. Linezolid-bupropion interaction as possible etiology of severe intermittent intraoperative hypertension? Anesthesiology 2004; 101:1487.</a></li><li class=\"breakAll\">Buproion hydrochloride tablet, extended release. US FDA prescribing information updated December, 2014. Available at US National Library of Medicine DailyMed website: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a435da9d-f6e8-4ddc-897d-8cd2bf777b21.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/96\" class=\"nounderline abstract_t\">Karkow DC, Kauer JF, Ernst EJ. Incidence of Serotonin Syndrome With Combined Use of Linezolid and Serotonin Reuptake Inhibitors Compared With Linezolid Monotherapy. J Clin Psychopharmacol 2017; 37:518.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/97\" class=\"nounderline abstract_t\">Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/98\" class=\"nounderline abstract_t\">Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998; 16:615.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/99\" class=\"nounderline abstract_t\">Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39:427.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/100\" class=\"nounderline abstract_t\">Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47:2775.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/101\" class=\"nounderline abstract_t\">Zoller M, Maier B, Hornuss C, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care 2014; 18:R148.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/102\" class=\"nounderline abstract_t\">Burdette SD, Trotman R. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. Clin Infect Dis 2015; 61:1315.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/103\" class=\"nounderline abstract_t\">Zurenko G, Bien P, Bensaci M, et al. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone. Ann Clin Microbiol Antimicrob 2014; 13:46.</a></li><li class=\"breakAll\">Tedizolid (Sivextro) Product Information. Merck and Co, Inc; Whitehouse, NJ 8/2017.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/105\" class=\"nounderline abstract_t\">Sahm DF, Deane J, Bien PA, et al. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 2015; 81:112.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/106\" class=\"nounderline abstract_t\">Lodise TP, Drusano GL. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin Infect Dis 2014; 58 Suppl 1:S28.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/107\" class=\"nounderline abstract_t\">Ong V, Flanagan S, Fang E, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos 2014; 42:1275.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/108\" class=\"nounderline abstract_t\">Bradley JS, Flanagan SD, Arrieta AC, et al. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents. Pediatr Infect Dis J 2016; 35:628.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/109\" class=\"nounderline abstract_t\">Lodise TP, Fang E, Minassian SL, Prokocimer PG. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother 2014; 58:7198.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/110\" class=\"nounderline abstract_t\">Flanagan S, Bartizal K, Minassian SL, et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013; 57:3060.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/111\" class=\"nounderline abstract_t\">Flanagan S, Minassian SL, Morris D, et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother 2014; 58:6471.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/112\" class=\"nounderline abstract_t\">Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009; 53:1271.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/113\" class=\"nounderline abstract_t\">Diamond JR, van Goor H, Ding G, Engelmyer E. Myofibroblasts in experimental hydronephrosis. Am J Pathol 1995; 146:121.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/114\" class=\"nounderline abstract_t\">Cosimi RA, Beik N, Kubiak DW, Johnson JA. Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review. Open Forum Infect Dis 2017; 4:ofx084.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/115\" class=\"nounderline abstract_t\">Britt RS, Evoy KE, Lee GC, et al. Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System. Drugs 2017; 77:1345.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/116\" class=\"nounderline abstract_t\">White BP, Barber KE, Stover KR. Ceftaroline for the treatment of methicillin-resistantStaphylococcus aureusbacteremia. Am J Health Syst Pharm 2017; 74:201.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/117\" class=\"nounderline abstract_t\">Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/118\" class=\"nounderline abstract_t\">Chan LC, Basuino L, Diep B, et al. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2015; 59:2960.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/119\" class=\"nounderline abstract_t\">Bhavnani SM, Hammel JP, Van Wart SA, et al. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2015; 59:372.</a></li><li class=\"breakAll\">Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 2006.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/121\" class=\"nounderline abstract_t\">Jacqueline C, Amador G, Caillon J, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010; 65:1749.</a></li><li class=\"breakAll\">Cottanoud P. et al. Ceftaroline fosamil against penicillin-sensitive and penicillin-resistant Streptococcus pneumoniae in an experimental meningitis model. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston 2010.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/123\" class=\"nounderline abstract_t\">Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006; 50:1376.</a></li><li class=\"breakAll\">Ceftaroline fosamil (Teflaro). Forest Pharmaceuticals, St. Louis, MO 5/2016.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/125\" class=\"nounderline abstract_t\">Balouch MA, Bajwa RJ, Hassoun A. Successful use of ceftaroline for the treatment of MRSA meningitis secondary to an infectious complication of lumbar spine surgery. J Antimicrob Chemother 2015; 70:624.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/126\" class=\"nounderline abstract_t\">Tattevin P, Boutoille D, Vitrat V, et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother 2014; 69:2010.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/127\" class=\"nounderline abstract_t\">Canut A, Isla A, Rodr&iacute;guez-Gasc&oacute;n A. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. Int J Antimicrob Agents 2015; 45:399.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/128\" class=\"nounderline abstract_t\">Le J, Bradley JS, Hingtgen S, et al. Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis. Pediatr Pulmonol 2017; 52:1424.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/129\" class=\"nounderline abstract_t\">Autry EB, Rybak JM, Leung NR, et al. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Pharmacotherapy 2016; 36:13.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/130\" class=\"nounderline abstract_t\">DiMondi VP, Drew RH, Chen LF. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy. Expert Rev Anti Infect Ther 2011; 9:567.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/131\" class=\"nounderline abstract_t\">Cannavino CR, Nemeth A, Korczowski B, et al. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J 2016; 35:752.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/132\" class=\"nounderline abstract_t\">Blumer JL, Ghonghadze T, Cannavino C, et al. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia. Pediatr Infect Dis J 2016; 35:760.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/133\" class=\"nounderline abstract_t\">Furtek KJ, Kubiak DW, Barra M, et al. High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother 2016; 71:2010.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/134\" class=\"nounderline abstract_t\">Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011; 66 Suppl 3:iii11.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/135\" class=\"nounderline abstract_t\">Corey GR, Rubinstein E, Stryjewski ME, et al. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis 2015; 60:787.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/136\" class=\"nounderline abstract_t\">Stryjewski ME, Lentnek A, O'Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis 2014; 14:289.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/137\" class=\"nounderline abstract_t\">Mendes RE, Farrell DJ, Sader HS, et al. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis 2015; 81:275.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/138\" class=\"nounderline abstract_t\">Pfaller MA, Sader HS, Flamm RK, et al. In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions. Microb Drug Resist 2017; 23:718.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/139\" class=\"nounderline abstract_t\">Arhin FF, Seguin DL, Belley A, Moeck G. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci. Diagn Microbiol Infect Dis 2017; 89:168.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/140\" class=\"nounderline abstract_t\">Patel R, Gallagher JC. Vancomycin-resistant enterococcal bacteremia pharmacotherapy. Ann Pharmacother 2015; 49:69.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/141\" class=\"nounderline abstract_t\">Lunde CS, Hartouni SR, Janc JW, et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009; 53:3375.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/142\" class=\"nounderline abstract_t\">Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005; 49:195.</a></li><li class=\"breakAll\">Telavancin (Vibativ) Product Information. Theravance Biopharma Antibiotics, Inc. San Francisco, CA 5/2016.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/144\" class=\"nounderline abstract_t\">Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004; 44:689.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/145\" class=\"nounderline abstract_t\">Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/146\" class=\"nounderline abstract_t\">Ero MP, Harvey NR, Harbert JL, et al. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis 2014; 38:235.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/147\" class=\"nounderline abstract_t\">Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40:374.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/148\" class=\"nounderline abstract_t\">Esposito S, Bianchini S. Dalbavancin for the treatment of paediatric infectious diseases. Eur J Clin Microbiol Infect Dis 2016; 35:1895.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/149\" class=\"nounderline abstract_t\">Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013; 75:304.</a></li><li class=\"breakAll\">Dalbavacin (Dalvance) Product Information. Durata Therapeutics U.S. Limited, Parsippany, NJ 01/2016.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/151\" class=\"nounderline abstract_t\">Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:940.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/152\" class=\"nounderline abstract_t\">Dunne MW, Puttagunta S, Giordano P, et al. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Clin Infect Dis 2016; 62:545.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/153\" class=\"nounderline abstract_t\">Gonzalez D, Bradley JS, Blumer J, et al. Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age. Pediatr Infect Dis J 2017; 36:645.</a></li><li class=\"breakAll\">Oritavancin (Orbactive) Product Information. The Medicines Company, Parsippany, NJ 10/2016.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/155\" class=\"nounderline abstract_t\">Stewart CL, Turner MS, Frens JJ, et al. Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections. Infect Dis Ther 2017; 6:277.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/156\" class=\"nounderline abstract_t\">Jones RN, Turnidge JD, Moeck G, et al. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. Antimicrob Agents Chemother 2015; 59:2405.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/157\" class=\"nounderline abstract_t\">Mendes RE, Woosley LN, Farrell DJ, et al. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. Antimicrob Agents Chemother 2012; 56:1639.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/158\" class=\"nounderline abstract_t\">Belley A, Lalonde-S&eacute;guin D, Arhin FF, Moeck G. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in anIn VitroPharmacokinetic/Pharmacodynamic Model of Infection. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/159\" class=\"nounderline abstract_t\">Rubino CM, Bhavnani SM, Moeck G, et al. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother 2015; 59:3365.</a></li><li class=\"breakAll\">ORBACTIV (oritavancin) for injection, for intravenous use. FDA package insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206334s002lbl.pdf (Accessed on February 02, 2016).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/161\" class=\"nounderline abstract_t\">Petersen PJ, Bradford PA, Weiss WJ, et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46:2595.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/162\" class=\"nounderline abstract_t\">Cercenado E, Cercenado S, G&oacute;mez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003; 52:138.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/163\" class=\"nounderline abstract_t\">Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007; 27:227.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/164\" class=\"nounderline abstract_t\">Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007; 45 Suppl 3:S184.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/165\" class=\"nounderline abstract_t\">Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006; 19:155.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/166\" class=\"nounderline abstract_t\">Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20:219S.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/167\" class=\"nounderline abstract_t\">Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64:63.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/168\" class=\"nounderline abstract_t\">Murphy TM, Deitz JM, Petersen PJ, et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44:3022.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/169\" class=\"nounderline abstract_t\">Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25:185.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/170\" class=\"nounderline abstract_t\">Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 Suppl 5:S303.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/171\" class=\"nounderline abstract_t\">Peleg AY, Adams J, Paterson DL. Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:2065.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/172\" class=\"nounderline abstract_t\">Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006; 28:1079.</a></li><li class=\"breakAll\">Tombs N. Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, San Francisco 1999.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/174\" class=\"nounderline abstract_t\">Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25:523.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/175\" class=\"nounderline abstract_t\">Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58:1221.</a></li><li class=\"breakAll\">Fang, G, Weiss, W, Scheld, W. Comparative efficacy of GAR-936 (GAR), a novel glycylcycline, alone and in combination with vancomycin against highly penicillin-resistant Streptococcus pneumoniae (PRSP) experimental meningitis in rabbits. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Toronto 2000.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/177\" class=\"nounderline abstract_t\">Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52:165.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/178\" class=\"nounderline abstract_t\">Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005; 17 Suppl 1:12.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/179\" class=\"nounderline abstract_t\">Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012; 34:496.</a></li><li class=\"breakAll\">US Food and Drug Administration (FDA). FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm (Accessed on May 05, 2015).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/181\" class=\"nounderline abstract_t\">Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.</a></li><li class=\"breakAll\">Wyeth. Tygacil - Prescribing Information. 2008.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/183\" class=\"nounderline abstract_t\">Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5:S354.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/184\" class=\"nounderline abstract_t\">Cunha BA, Baron J, Cunha CB. Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited. Expert Rev Anti Infect Ther 2017; 15:257.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/185\" class=\"nounderline abstract_t\">Aeschlimann JR, Rybak MJ. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob Agents Chemother 1998; 42:2188.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/186\" class=\"nounderline abstract_t\">Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44:251.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/187\" class=\"nounderline abstract_t\">Allington DR, Rivey MP. Quinupristin/dalfopristin: a therapeutic review. Clin Ther 2001; 23:24.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/188\" class=\"nounderline abstract_t\">Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999; 58:1061.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/189\" class=\"nounderline abstract_t\">Schmitz FJ, Witte W, Werner G, et al. Characterization of the translational attenuator of 20 methicillin-resistant, quinupristin/dalfopristin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2001; 48:939.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/190\" class=\"nounderline abstract_t\">Low DE, Nadler HL. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother 1997; 39 Suppl A:53.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/191\" class=\"nounderline abstract_t\">Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/192\" class=\"nounderline abstract_t\">Werner G, Klare I, Heier H, et al. Quinupristin/dalfopristin-resistant enterococci of the satA (vatD) and satG (vatE) genotypes from different ecological origins in Germany. Microb Drug Resist 2000; 6:37.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/193\" class=\"nounderline abstract_t\">Malbruny B, Canu A, Bozdogan B, et al. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:2200.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/194\" class=\"nounderline abstract_t\">Karanika M, Prati A, Kiritsi M, et al. Reduced susceptibility to quinupristin/dalfopristin in Enterococcus faecium in Greece without prior exposure to the agent. Int J Antimicrob Agents 2008; 31:55.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/195\" class=\"nounderline abstract_t\">El Solh N, Allignet J. Staphylococcal resistance to streptogramins and related antibiotics. Drug Resist Updat 1998; 1:169.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/196\" class=\"nounderline abstract_t\">Bergeron M, Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimicrob Chemother 1997; 39 Suppl A:129.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/197\" class=\"nounderline abstract_t\">Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161:753.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/198\" class=\"nounderline abstract_t\">Summers M, Misenhimer GR, Antony SJ. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin. South Med J 2001; 94:353.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/199\" class=\"nounderline abstract_t\">Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999; 44 Suppl A:37.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/200\" class=\"nounderline abstract_t\">Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antimicrobial-agents-for-treatment-of-methicillin-resistant-staphylococcus-aureus-and-vancomycin-resistant-enterococcus/abstract/201\" class=\"nounderline abstract_t\">Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001; 32:e83.</a></li><li class=\"breakAll\">Quinupristin-dalfopristion (Synercid) Product Information. Pfizer, New York, NY 8/2017.</li></ol></div><div id=\"topicVersionRevision\">Topic 466 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H34\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H746396028\" id=\"outline-link-H746396028\">VANCOMYCIN</a></li><li><a href=\"#H13034132\" id=\"outline-link-H13034132\">DAPTOMYCIN</a><ul><li><a href=\"#H13034159\" id=\"outline-link-H13034159\">Mechanism and pharmacodynamics</a></li><li><a href=\"#H13034166\" id=\"outline-link-H13034166\">Pharmacokinetics</a></li><li><a href=\"#H13034173\" id=\"outline-link-H13034173\">Adverse effects</a></li><li><a href=\"#H13034180\" id=\"outline-link-H13034180\">Use in pregnancy</a></li><li><a href=\"#H13034187\" id=\"outline-link-H13034187\">Drug interactions</a></li><li><a href=\"#H13034194\" id=\"outline-link-H13034194\">Dosing and administration</a></li><li><a href=\"#H13034201\" id=\"outline-link-H13034201\">Monitoring</a></li></ul></li><li><a href=\"#H2\" id=\"outline-link-H2\">LINEZOLID</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Mechanism, resistance, and pharmacodynamics</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Pharmacokinetics</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Adverse effects</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Use in pregnancy</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Drug interactions</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Dosing and administration</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Monitoring</a></li></ul></li><li><a href=\"#H1402177436\" id=\"outline-link-H1402177436\">TEDIZOLID</a><ul><li><a href=\"#H340582793\" id=\"outline-link-H340582793\">Mechanism, resistance, and pharmacodynamics</a></li><li><a href=\"#H929709809\" id=\"outline-link-H929709809\">Pharmacokinetics</a></li><li><a href=\"#H1109703099\" id=\"outline-link-H1109703099\">Adverse effects</a></li><li><a href=\"#H3181915815\" id=\"outline-link-H3181915815\">Use in pregnancy</a></li><li><a href=\"#H497242074\" id=\"outline-link-H497242074\">Drug interactions</a></li><li><a href=\"#H19053993\" id=\"outline-link-H19053993\">Dosing and administration</a></li><li><a href=\"#H2254848824\" id=\"outline-link-H2254848824\">Monitoring</a></li></ul></li><li><a href=\"#H13032953\" id=\"outline-link-H13032953\">CEFTAROLINE</a><ul><li><a href=\"#H13032961\" id=\"outline-link-H13032961\">Mechanism and pharmacodynamics</a></li><li><a href=\"#H13032969\" id=\"outline-link-H13032969\">Pharmacokinetics</a></li><li><a href=\"#H13032977\" id=\"outline-link-H13032977\">Dosing and administration</a></li><li><a href=\"#H13032985\" id=\"outline-link-H13032985\">Adverse effects</a></li><li><a href=\"#H13032993\" id=\"outline-link-H13032993\">Use in pregnancy</a></li><li><a href=\"#H13033001\" id=\"outline-link-H13033001\">Drug interactions</a></li></ul></li><li><a href=\"#H681949725\" id=\"outline-link-H681949725\">TELAVANCIN</a><ul><li><a href=\"#H681949617\" id=\"outline-link-H681949617\">Mechanism and pharmacodynamics</a></li><li><a href=\"#H681949623\" id=\"outline-link-H681949623\">Pharmacokinetics</a></li><li><a href=\"#H681949629\" id=\"outline-link-H681949629\">Adverse effects</a></li><li><a href=\"#H681949731\" id=\"outline-link-H681949731\">Use in pregnancy</a></li><li><a href=\"#H681949635\" id=\"outline-link-H681949635\">Drug interactions</a></li><li><a href=\"#H681949641\" id=\"outline-link-H681949641\">Dosing and administration</a></li><li><a href=\"#H681949647\" id=\"outline-link-H681949647\">Monitoring</a></li></ul></li><li><a href=\"#H681949737\" id=\"outline-link-H681949737\">DALBAVANCIN</a><ul><li><a href=\"#H681949653\" id=\"outline-link-H681949653\">Mechanism and pharmacodynamics</a></li><li><a href=\"#H681949659\" id=\"outline-link-H681949659\">Pharmacokinetics</a></li><li><a href=\"#H681949665\" id=\"outline-link-H681949665\">Adverse effects</a></li><li><a href=\"#H681949743\" id=\"outline-link-H681949743\">Use in pregnancy</a></li><li><a href=\"#H681949671\" id=\"outline-link-H681949671\">Drug interactions</a></li><li><a href=\"#H681949677\" id=\"outline-link-H681949677\">Dosing and administration</a></li><li><a href=\"#H681949683\" id=\"outline-link-H681949683\">Monitoring</a></li></ul></li><li><a href=\"#H681949749\" id=\"outline-link-H681949749\">ORITAVANCIN</a><ul><li><a href=\"#H681949689\" id=\"outline-link-H681949689\">Mechanism and pharmacodynamics</a></li><li><a href=\"#H681949695\" id=\"outline-link-H681949695\">Pharmacokinetics</a></li><li><a href=\"#H681949701\" id=\"outline-link-H681949701\">Adverse effects</a></li><li><a href=\"#H681949707\" id=\"outline-link-H681949707\">Drug interactions</a></li><li><a href=\"#H681949713\" id=\"outline-link-H681949713\">Dosing and administration</a></li><li><a href=\"#H681949719\" id=\"outline-link-H681949719\">Monitoring</a></li></ul></li><li><a href=\"#H931305133\" id=\"outline-link-H931305133\">TIGECYCLINE</a><ul><li><a href=\"#H931305240\" id=\"outline-link-H931305240\">Mechanism and pharmacodynamics</a></li><li><a href=\"#H931305326\" id=\"outline-link-H931305326\">Pharmacokinetics</a></li><li><a href=\"#H931305440\" id=\"outline-link-H931305440\">Adverse effects</a></li><li><a href=\"#H931305502\" id=\"outline-link-H931305502\">Use in pregnancy</a></li><li><a href=\"#H931305536\" id=\"outline-link-H931305536\">Drug interactions</a></li><li><a href=\"#H931305556\" id=\"outline-link-H931305556\">Dosing and administration</a></li><li><a href=\"#H931305576\" id=\"outline-link-H931305576\">Monitoring</a></li></ul></li><li><a href=\"#H931303774\" id=\"outline-link-H931303774\">QUINUPRISTIN-DALFOPRISTIN</a><ul><li><a href=\"#H931303833\" id=\"outline-link-H931303833\">Mechanism and pharmacodynamics</a></li><li><a href=\"#H931303969\" id=\"outline-link-H931303969\">Pharmacokinetics</a></li><li><a href=\"#H931304059\" id=\"outline-link-H931304059\">Adverse effects</a></li><li><a href=\"#H931304133\" id=\"outline-link-H931304133\">Use in pregnancy</a></li><li><a href=\"#H931304139\" id=\"outline-link-H931304139\">Drug interactions</a></li><li><a href=\"#H931304159\" id=\"outline-link-H931304159\">Dosing and administration</a></li><li><a href=\"#H931304193\" id=\"outline-link-H931304193\">Monitoring</a></li></ul></li><li><a href=\"#H34\" id=\"outline-link-H34\">SUMMARY</a></li><li><a href=\"#H2491130045\" id=\"outline-link-H2491130045\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=serotonin-syndrome-serotonin-toxicity\" class=\"medical medical_review\">Serotonin syndrome (serotonin toxicity)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-enterococcal-infections\" class=\"medical medical_review\">Treatment of enterococcal infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults\" class=\"medical medical_review\">Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults</a></li></ul></div></div>","javascript":null}